Inhibition of gsk-3 induces differentiation and impaired glucose metabolism in renal cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 2, 2014, Pages 285-296

  Pal, Krishnendu ^a   Cao, Ying ^a   Gaisina, Irina N ^c   Bhattacharya, Santanu ^a   Dutta, Shamit K ^a   Wang, Enfeng ^a   Gunosewoyo, Hendra ^c   Kozikowski, Alan P ^c   Billadeau, Daniel D ^a,b   Mukhopadhyay, Debabrata ^a  

^a Departments of Biochemistry and Molecular Biology   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9ING 41; BETA ACTIN; CADHERIN; CYCLIN D; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; MALEIMIDE DERIVATIVE; UNCLASSIFIED DRUG; 3-(5-FLUOROBENZOFURAN-3-YL)-4-(5-METHYL-5H-(1,3)DIOXOLO(4,5-F)INDOL-7-YL)-PYRROLE-2,5-DIONE; ENZYME INHIBITOR; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3 BETA; INDOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS ASSAY; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL DEDIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DISORDERS OF CARBOHYDRATE METABOLISM; DNA SYNTHESIS; ENERGY BALANCE; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; G2 PHASE CELL CYCLE CHECKPOINT; GLUCOSE METABOLISM; GLYCOGEN METABOLISM; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CELL DIFFERENTIATION; CHEMICAL STRUCTURE; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; KIDNEY NEOPLASMS; METABOLISM; NUDE MOUSE; PHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; AUTOPHAGY; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MALEIMIDES; MICE, NUDE; MICROSCOPY, CONFOCAL; MOLECULAR STRUCTURE; RNA INTERFERENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894218696     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0681     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
2. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer. 1997;80:1198-220
3. Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol. 2001;19:148-54
4. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006;24:5601-8
5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90
6. Motzer RJ, Molina AM. Targeting renal cell carcinoma. J Clin Oncol. 2009;27:3274-6
7. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58:398-406
8. Grunwald V, Kalanovic D, Merseburger AS. Management of sunitinibrelated adverse events: an evidence-and expert-based consensus approach. World J Urol 2010;28:343-51
9. Oya M, Ohtsubo M, Takayanagi A, Tachibana M, Shimizu N, Murai M. Constitutive activation of nuclear factor-kappa B prevents TRAILinduced apoptosis in renal cancer cells. Oncogene 2001;20:3888-96
10. Oya M, Takayanagi A, Horiguchi A, Mizuno R, Ohtsubo M, Marumo K, et al. Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma. Carcinogenesis 2003;24: 377-84
11. An J, Sun Y, Fisher M, Rettig MB. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factorkappa B dependent. Mol Cancer Ther 2004;3:727-36
12. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappa B activation. Nature 2000;406:86-90
13. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005;65:2076-81
14. Ougolkov AV, Bone ND, Fernandez-Zapico ME, Kay NE, Billadeau DD. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 2007;110: 735-42
15. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980;107:519-27
16. Parker PJ, Caudwell FB, Cohen P. Glycogen synthase from rabbit skeletal muscle; effect of insulin on the state of phosphorylation of the seven phosphoserine residues in vivo. Eur J Biochem 1983;130: 227-34
17. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. Embo J 1990;9:2431-8
18. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001;359:1-16
19. Woodgett JR. Judging a protein by more than its name: GSK-3. Sci STKE 2001;2001:re12
20. Dorn GWII, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005;115:527-37
21. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003;116:1175-86
22. Force T, Woodgett JR. Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem 2009;284:9643-7
23. Xu C, Kim NG, Gumbiner BM. Regulation of protein stability by GSK3 mediated phosphorylation. Cell Cycle 2009;8:4032-9
24. Kaidanovich-Beilin O, Woodgett JR. GSK-3: functional insights from cell biology and animal models. Front Mol Neurosci 2011;4:40
25. Cheng H, Woodgett J, Maamari M, Force T. Targeting GSK-3 family members in the heart: a very sharp double-edged sword. J Mol Cell Cardiol 2011;51:607-13
26. Luo J. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 2009;273:194-200
27. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 2007;32: 577-95
28. Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, Zhang W, et al. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res 2008;68:6643-51
29. Tan J, Zhuang L, Leong HS, Iyer NG, Liu ET, Yu Q. Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res 2005;65: 9012-20
30. Bilim V, Ougolkov A, Yuuki K, Naito S, Kawazoe H, Muto A, et al. Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br J Cancer 2009;101:2005-14
31. Kim HM, Kim CS, Lee JH, Jang SJ, Hwang JJ, Ro S, et al. CG0009, a novel glycogen synthase kinase 3 inhibitor, induces cell death through cyclin D1 depletion in breast cancer cells. PLoS ONE 2013; 8:e60383
32. Gaisina IN, Gallier F, Ougolkov AV, Kim KH, Kurome T, Guo S, et al. From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. J Med Chem 2009;52:1853-63
33. Hilliard TS, Gaisina IN, Muehlbauer AG, Gaisin AM, Gallier F, Burdette JE. Glycogen synthase kinase 3beta inhibitors induce apoptosis in ovarian cancer cells and inhibit in vivo tumor growth. Anticancer Drugs 2011;22:978-85
34. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelialmesenchymal transition. Nat Cell Biol 2004;6:931-40
35. Bachelder RE, Yoon SO, Franci C, de Herreros AG, Mercurio AM. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol 2005;168:29-33
36. Zheng H, Li W, Wang Y, Liu Z, Cai Y, Xie T, et al. Glycogen synthase kinase-3 beta regulates Snail and beta-catenin expression during Fasinduced epithelial-mesenchymal transition in gastrointestinal cancer. Eur J Cancer 2013;49:2734-46
37. Kao SH, Wang WL, Chen CY, Chang YL, Wu YY, Wang YT, et al. GSK3beta controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug. Oncogene 2013 Jul 15. [Epub ahead of print].]
38. Thedieck C, Kuczyk M, Klingel K, Steiert I, Muller CA, Klein G. Expression of Ksp-cadherin during kidney development and in renal cell carcinoma. Br J Cancer 2005;92:2010-7
39. Li X, Zhang Z, Xin D, Chua CW, Wong YC, Leung SC, et al. Prognostic significance of Id-1 and its association with EGFR in renal cell cancer. Histopathology 2007;50:484-90
40. Buller CL, Loberg RD, Fan MH, Zhu Q, Park JL, Vesely E, et al. A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Am J Physiol Cell Physiol 2008; 295:C836-43
41. Suzuki T, Bridges D, Nakada D, Skiniotis G, Morrison SJ, Lin JD, et al. Inhibition of AMPK catabolic action by GSK3. Mol Cell 2013;50:407-19
42. Gavilan E, Sanchez-Aguayo I, Daza P, Ruano D. GSK-3beta signaling determines autophagy activation in the breast tumor cell line MCF7 and inclusion formation in the non-tumor cell line MCF10A in response to proteasome inhibition. Cell Death Dis 2013;4:e572
43. Zhai P, Sciarretta S, Galeotti J, Volpe M, Sadoshima J. Differential roles of GSK-3beta during myocardial ischemia and ischemia/reperfusion. Circ Res 2011;109:502-11
44. Parr C, Carzaniga R, Gentleman SM, Van Leuven F, Walter J, Sastre M. Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-beta precursor protein. Mol Cell Biol 2012;32:4410-8
45. Zhou X, Zhou J, Li X, Guo C, Fang T, Chen Z. GSK-3beta inhibitors suppressed neuroinflammation in rat cortex by activating autophagy in ischemic brain injury. Biochem Biophys Res Commun 2011;411:271-5
46. Zhou J, Freeman TA, Ahmad F, Shang X, Mangano E, Gao E, et al. GSK-3alpha is a central regulator of age-related pathologies in mice. J Clin Invest 2013;123:1821-32
47. Yang J, Takahashi Y, Cheng E, Liu J, Terranova PF, Zhao B, et al. GSK-3beta promotes cell survival by modulating Bif-1-dependent autophagy and cell death. J Cell Sci 2010;123:861-70
48. Lin SY, Li TY, Liu Q, Zhang C, Li X, Chen Y, et al. GSK3-TIP60-ULK1 signaling pathway links growth factor deprivation to autophagy. Science 2012;336:477-81
49. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499: 43-9
50. Woodard J, Joshi S, Viollet B, Hay N, Platanias LC. AMPK as a therapeutic target in renal cell carcinoma. Cancer Biol Ther 2010;10: 1168-77.